Clinical Trial Update: Study Of The Pharmacokinetics And Safety Of Voriconazole In Children 2 To Less Than 15 Years Old Who Are At High Risk For Systemic Fungal Infection [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the pharmacokinetics and safety of voriconazole in children aged 2 to less than 15 years at high risk for systemic fungal infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aspergilloma
• Aspergillosis

Drugs mentioned

• VFEND (Voriconazole)

Snippet

Sponsor: Pfizer | Conditions: Aspergillosis, Aspergilloma | Phase 2 | Status: COMPLETED | Results posted: 2014-05-09